97 results on '"Smith, Lisa L."'
Search Results
52. Editorial
53. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
54. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
55. Successful strategies for recruiting African Americans to prevention trials
56. Understanding the factors that predict victim retraction in police reported allegations of intimate partner violence.
57. Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia
58. the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL
59. Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo
60. The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia
61. Genetic heterogeneity of diffuse large B-cell lymphoma
62. The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing
63. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
64. Amateur versus professional
65. Arizona Activity Frequency Questionnaire--Modified
66. Photobleaching with phloxine B sensitizer to reduce food matrix interference for detection of Escherichia coli serotype O157:H7 in fresh spinach by flow cytometry
67. Exploring the Disclosure of Forensic Evidence in Police Interviews with Suspects
68. From the Editor
69. Validation of the factor structure and predictive validity of the Forensic Evidence Evaluation Bias Scale for robbery and sexual assault trial scenarios
70. Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression.
71. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells
72. Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease
73. Identifying and measuring juror pre-trial bias for forensic evidence: development and validation of the Forensic Evidence Evaluation Bias Scale
74. Physiological Measurement of Crime Scene Investigator Stress
75. Vitamin C Status is associated with Physical Fitness and Activity Indices in College Men: a cross‐sectional study
76. Forensic Evidence Evaluation Bias Scale
77. An Investigation into the Crime Scene Characteristics That Differentiate a Car Key Burglary from a Regular Domestic Burglary
78. The Relationship Between Deprivation and Forensic Material Recovered from Stolen Vehicles: Is it Affected by Vehicle Condition and Tidiness?
79. Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines
80. Examining the Factors That Differentiate a Car Key Burglary from a Regular Domestic Burglary
81. Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
82. The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.
83. The Effect of Case Context on Mock Jurors’ Perceptions of DNA Evidence
84. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
85. Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
86. Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.
87. Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).
88. Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).
89. Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.
90. The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL.
91. The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.
92. Validation of the factor structure and predictive validity of the Forensic Evidence Evaluation Bias Scale for robbery and sexual assault trial scenarios.
93. Amateur versus professional: Does the recovery of forensic evidence differ depending on who assesses the crime scene?
94. Procedures for enhancing the utility of the metallothionein promoter for the regulated expression of downstream open reading frames
95. Communities and tree seedling distribution in Quercus rubra- and Prunus serotina-dominated forests in southwestern Pennsylvania
96. Amino acid concentrations in extrafloral nectar of Impatiens sultaniincrease after simulated herbivory
97. BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.